ImmuVia Partners with Quantori to Accelerate Cancer Therapy Development

Biotechnology company selects Q-Scientist platform to streamline computational workflows and compress timelines for lead candidate IMV-M

Apr. 15, 2026 at 5:48am

Got story updates? Submit your updates here. ›

A highly textured, abstract painting in soft earth tones featuring sweeping geometric shapes, concentric circles, and precise botanical spirals, visually representing the complex molecular interactions and pharmacological properties of ImmuVia's cancer therapy platform.A conceptual illustration depicting the advanced computational modeling that enables ImmuVia to accelerate the development of its novel cancer therapy platform.Cambridge Today

ImmuVia Inc., a biotechnology company developing first-in-class therapies for solid tumors, has selected Quantori, a leading provider of digital transformation services and technology for the life sciences and healthcare industries, as a strategic technology partner. ImmuVia will deploy Quantori's Q-Scientist platform to streamline computational workflows across its preclinical programs, with the goal of compressing development timelines and reducing costs as it advances its lead candidate, IMV-M, towards clinical trials.

Why it matters

ImmuVia's proprietary Cancerlysin platform represents a differentiated approach to harnessing the biology of apoptosis, or programmed cell death, to selectively kill tumor cells. By partnering with Quantori, ImmuVia aims to leverage advanced computational modeling and simulation capabilities to optimize its lead candidate IMV-M more efficiently, ultimately accelerating the development of this promising new cancer therapy.

The details

ImmuVia's lead candidate, IMV-M, is a bispecific antibody that first binds to the MUC16 protein overexpressed on certain solid tumors, and then activates the Death Receptor 5 pathway to trigger apoptosis. This conditional activation is designed to enhance potency and widen the therapeutic window. Through the partnership, Quantori will support ImmuVia's preclinical programs in three key areas: molecular modeling and simulation to optimize candidate molecules, in silico pharmacology to model the drug's behavior in the tumor microenvironment, and regulatory data preparation to compress timelines for IND-enabling studies.

  • ImmuVia announced the partnership with Quantori on April 15, 2026.
  • ImmuVia's lead candidate, IMV-M, is advancing towards IND-enabling studies.

The players

ImmuVia Inc.

A biotechnology company developing first-in-class therapies for solid tumors, including its lead candidate IMV-M which targets MUC16-positive cancers.

Quantori

A leading provider of digital transformation services and technology for the life sciences and healthcare industries, offering the Q-Scientist platform to streamline computational workflows.

Iosif M. Gershteyn

Chief Executive Officer at ImmuVia.

Yuriy Gankin, PhD

Chief Scientific Officer at Quantori.

Got photos? Submit your photos here. ›

What they’re saying

“ImmuVia is a biology company. Our edge is the science behind IMV-M™ and the Cancerlysin™ platform. What we need from technology partners is straightforward: help us do our work faster and at lower cost. Quantori's platform does exactly that. It lets a lean team operate with the analytical throughput of a large organization, that's a practical advantage we intend to leverage.”

— Iosif M. Gershteyn, Chief Executive Officer at ImmuVia

“What makes this collaboration compelling is the quality of the underlying science. ImmuVia's platform represents a genuinely differentiated approach to harnessing the biology of apoptosis, and the computational demands of a program this sophisticated are exactly where Q-Scientist delivers the most value. We can construct detailed in silico models of IMV-M's behavior - its conformational dynamics, its interactions within the tumor microenvironment - and deliver those insights at a speed and cost that would be impossible to replicate through traditional methods.”

— Yuriy Gankin, PhD, Chief Scientific Officer at Quantori

What’s next

ImmuVia's lead candidate, IMV-M, is advancing towards IND-enabling studies as the company continues its partnership with Quantori to streamline computational workflows and accelerate development.

The takeaway

By leveraging advanced computational modeling and simulation capabilities through its partnership with Quantori, ImmuVia aims to optimize the development of its novel cancer therapy IMV-M more efficiently, ultimately bringing this promising first-in-class treatment to patients faster.